Patents by Inventor Stephan D. Parent

Stephan D. Parent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Forms of rifaximin and uses thereof
    Patent number: 8513275
    Abstract: The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: August 20, 2013
    Assignee: Salix Pharmaceuticals, Ltd
    Inventors: Yiduo Wu, Stephan D. Parent, Nathan Carl Schultheiss, Melanie Janelle Bevill, Petinka Vlahova, Travis L. Houston
  • Forms of rifaximin and uses thereof
    Patent number: 8507517
    Abstract: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: August 13, 2013
    Assignee: Salix Pharmaceuticals, Ltd
    Inventors: Stephan D. Parent, Lisa Lynn McQueen, Patricia Andres, Paul Schields, Yiduo Wu, Fei Ding, Jared Peters Smit
  • Tablet formulation of ezatiostat
    Patent number: 8361971
    Abstract: Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: January 29, 2013
    Assignee: Telik, Inc.
    Inventors: Robert T. Lum, Stephan D. Parent, Chunsheng Qiao, Steven R. Schow
  • NOVEL FORMS OF CDDO METHYL ESTER
    Publication number: 20120330050
    Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.
    Type: Application
    Filed: June 29, 2012
    Publication date: December 27, 2012
    Inventors: John WALLING, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, JR.
  • Forms of CDDO methyl ester
    Patent number: 8309601
    Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: November 13, 2012
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, Jr.
  • NOVEL SALTS AND POLYMORPHS OF DESAZADESFERRITHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS
    Publication number: 20120270911
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Application
    Filed: October 6, 2011
    Publication date: October 25, 2012
    Applicant: FERROKIN BIOSCIENCES, INC.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20120264774
    Abstract: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: June 22, 2012
    Publication date: October 18, 2012
    Inventors: Stephan D. Parent, Lisa L. McQueen, Patricia Andres, Paul Schields, Yiduo Wu, Fei Ding, Jared P. Smit
  • Quinine sulfate/bisulfate solid complex; methods of making; and methods of use thereof
    Patent number: 8258155
    Abstract: Disclosed are new quinine sulfate/bisulfate solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: September 4, 2012
    Assignee: Mutual Pharmaceutical Company, Inc.
    Inventors: Tong Sun, Shawn Watson, Wei Lai, Stephan D. Parent
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20120207833
    Abstract: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: February 10, 2012
    Publication date: August 16, 2012
    Inventors: Stephan D. Parent, Lisa L. McQueen, Patricia Andres, Paul Schields, Yiduo Wu, Fei Ding, Jared P. Smit
  • NOVEL SALTS AND POLYMORPHS OF DESAZADESFERRITHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS
    Publication number: 20120202857
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Application
    Filed: August 4, 2011
    Publication date: August 9, 2012
    Applicant: FERROKIN BIOSCIENCES, INC.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, JR., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • Forms of rifaximin and uses thereof
    Patent number: 8227482
    Abstract: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: July 24, 2012
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: Stephan D. Parent, Lisa Lynn McQueen, Patricia Andres, Paul Schields, Yiduo Wu, Fei Ding, Jared Peters Smit
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20120108620
    Abstract: The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods.
    Type: Application
    Filed: June 3, 2011
    Publication date: May 3, 2012
    Applicant: SALIX PHARMACEUTICALS, LTD.
    Inventors: Yiduo Wu, Stephan D. Parent, Nathan Carl Schultheiss, Melanie Janelle Bevill, Petinka Vlahova, Travis L. Houston
  • NOVEL FORMS OF CDDO METHYL ESTER
    Publication number: 20120071684
    Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.
    Type: Application
    Filed: November 29, 2011
    Publication date: March 22, 2012
    Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, JR.
  • TABLET FORMULATION OF EZATIOSTAT
    Publication number: 20120021054
    Abstract: Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.
    Type: Application
    Filed: September 27, 2011
    Publication date: January 26, 2012
    Inventors: Robert T. Lum, Stephan D. Parent, Chunsheng Qiao, Steven R. Schow
  • Forms of CDDO methyl ester
    Patent number: 8088824
    Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.
    Type: Grant
    Filed: August 13, 2008
    Date of Patent: January 3, 2012
    Assignee: Reata Pharmaceuticals Inc.
    Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, Jr.
  • CRYSTALLINE EZATIOSTAT HYDROCHLORIDE ANSOLVATE
    Publication number: 20110301088
    Abstract: Crystalline ezatiostat hydrochloride ansolvate form D is more stable and/or more soluble that various solvated crystalline polymorphic forms of ezatiostat hydrochloride.
    Type: Application
    Filed: March 4, 2011
    Publication date: December 8, 2011
    Inventors: Stephan D. Parent, Steven R. Schow
  • TABLET FORMULATION OF EZATIOSTAT
    Publication number: 20110300215
    Abstract: Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.
    Type: Application
    Filed: March 29, 2011
    Publication date: December 8, 2011
    Inventors: Robert T. Lum, Stephan D. Parent, Chunsheng Qiao, Steven R. Schow
  • Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
    Patent number: 8063227
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: November 22, 2011
    Assignee: Ferrokin Biosciences, Inc.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • COLCHICINE SOLID COMPLEX; METHODS OF MAKING; AND METHODS OF USE THEREOF
    Publication number: 20110245336
    Abstract: Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof.
    Type: Application
    Filed: June 13, 2011
    Publication date: October 6, 2011
    Inventors: Tong Sun, David Jonaitis, Stephan D. Parent
  • Colchicine solid complex; methods of making; and methods of use thereof
    Patent number: 8003700
    Abstract: Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulation prepared therefrom and uses thereof.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: August 23, 2011
    Assignee: Mutual Pharamaceutical Company, Inc.
    Inventors: Tong Sun, David Jonaitis, Stephan D. Parent